Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Matinas Biopharma Holdings Inc. (MTNB:NYSE), powered by AI.
Matinas Biopharma Holdings Inc. is currently trading at $0.72. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Matinas Biopharma Holdings Inc. on Alpha Lenz.
View Matinas Biopharma Holdings Inc.'s valuation metrics on Alpha Lenz.
“Matinas Biopharma Holdings Inc.'s ROE is -166.6%. Explore profitability and growth together.”
Ask for details →Matinas Biopharma Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for unmet medical needs. Its primary function lies in the creation and advancement of lipid nano-crystal delivery technology, which aims to enhance the bioavailability and efficacy of pharmaceuticals. This company has a strategic focus on infectious diseases and rare disorders, addressing significant gaps in existing therapeutic options. Matinas Biopharma's innovative delivery platforms are designed to optimize drug exposure, enhance safety profiles, and enable oral dosing of complex molecules, which can potentially transform the treatment landscape. Operating within the biotechnology sector, the company impacts both healthcare and pharmaceutical industries by striving to improve the delivery and accessibility of treatments. By leveraging its proprietary technology, Matinas Biopharma plays a crucial role in the market by providing advanced solutions that could potentially reformulate how certain medications are administered, contributing to a broader goal of enhancing patient outcomes and quality of life.
“Matinas Biopharma Holdings Inc.'s ROE is -166.6%. Explore profitability and growth together.”
Ask for details →Matinas Biopharma Holdings Inc. (ticker: MTNB) is a company listed on NYSE in the Healthcare sector (Biotechnology). It has approximately 3 employees.
The current price is $0.72 with a P/E ratio of -x and P/B of -x.
ROE is -166.59%.